Top Vaccine manufacturer Pfizer and its partner BioNTech said their Covid-19 vaccine is safe and 90.7 per cent effective against symptomatic coronavirus in children aged 5 to 11. The conglomerates revealed the data in a document posted on Friday ahead of a meeting of advisers to the Food and Drug Administration (FDA) scheduled for October 26.
Pfizer and BioNTech are applying Food and Drug Administration, the federal agency of the Department of Health and Human Services, for emergency use authorization of a two-dose regimen of their 10-microgram dose for children of the mentioned age group.
The two doses would be administered three weeks apart. The data show that the two-dose primary series of the vaccine given to kids from 5 to less than 12 years of age confers a high degree of protective efficacy against Covid-19 during a period when the Delta variant of concern predominates in the US. The FDA's Vaccines and Related Biological Products Advisory Committee is scheduled to meet on October 26 to discuss whether to authorise the jab. If endorsed, it would be the first Covid-19 vaccine for younger children. Notably, The Pfizer-BioNTech vaccine is currently fully approved for people ages 16 and older and has an EUA for children aged 12 to 15.